Mini Bronchoalveolar Lavage for Lung Injury
Trial Summary
What is the purpose of this trial?
The goal of this observational clinical trial is to learn about the role white blood cells (macrophages) play in lung inflammation in people with Acute Respiratory Distress Syndrome (ARDS). The main questions it aims to answer are: 1. How does the immune system respond to different kinds of lung injury and inflammation and how do those processes differ from each other? 2. What roles do the cells that live in the lungs (macrophages) play in turning off inflammation? How does their role differ from other cells that are called to the lung to help repair injury (recruited macrophages)? 3. Will more frequent testing of lung cell samples help reduce the time it takes to start treatment for ventilator-associated pneumonia (VAP) and therefore reduce the rates of initial therapy failure? Participants will be in the intensive care unit (ICU) on a mechanical ventilator (machine that helps patients breathe) because they have ARDS or are on a mechanical ventilator for some other reason (control group). The following will happen: 1. Participants will be given 100% oxygen through the breathing machine (mechanical ventilator) for 3-5 minutes. This is called pre-oxygenation. 2. A lung specialist (pulmonologist), a member of Dr. Janssen's research team, or respiratory therapist will place small amount of saline into the lung using a long catheter going through the breathing tube. 3. The fluid will be removed with suction and will be sent to the laboratory for testing. 4. This will be repeated two more times over the course of 10 days, or less if participants are taken off of the ventilator. The procedure will be performed no more than three times. 5. Two nasal brushings will be taken from the participants' nose. 6. Approximately 3 tablespoons of blood will be removed by putting a needle into the participants vein. This is the standard method used to obtain blood for tests. A total of 9 tablespoons will be taken for research purposes over the course of this study 7. Data including the participants age, sex, severity of illness, and other medical conditions will be recorded to determine how these can affect the white blood cells. 8. If bacteria are isolated from the fluid in the participants lung, the participants' physician may choose to place the participants on antibiotics to treat an infection. 9. A follow-up phone call may be made by a member of the research team after discharge from the hospital. At this time, the participant may be invited to participate in the Post-ICU clinic at National Jewish Health.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the research team or your doctor.
What data supports the effectiveness of the treatment Non-Bronchoscopic Mini Bronchoalveolar Lavage?
Non-bronchoscopic bronchoalveolar lavage (NB-BAL) has been shown to be a valuable method for obtaining lung samples in children with small airways, providing clinically significant information in 85% of cases without needing more invasive procedures. This suggests that NB-BAL can effectively gather important lung information, which may help in managing lung conditions.12345
Is Mini Bronchoalveolar Lavage safe for humans?
Non-bronchoscopic bronchoalveolar lavage (NB-BAL) has been studied for safety in various groups, including preterm neonates and critically ill children. While generally considered safe, there can be potential effects on breathing and blood flow, especially in patients on mechanical ventilation.25678
How does the mini bronchoalveolar lavage treatment differ from other treatments for lung injury?
Mini bronchoalveolar lavage is unique because it is a non-invasive procedure that uses a sterile, disposable feeding tube to collect lung fluid samples in mechanically ventilated infants, providing a safer and less costly alternative to traditional bronchoscopy, which is not feasible in small infants due to their small airways.124910
Research Team
Eligibility Criteria
This trial is for ICU patients on mechanical ventilation due to ARDS or similar conditions, expected to remain ventilated for at least 48 hours. It's not suitable for those with chronic lung diseases, recent immunosuppressant use, history of organ transplant, severe bleeding risks, a directive against life-sustaining treatment, morbid state with less than 14 days survival expectancy or pregnancy.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Observation
Participants undergo procedures to collect lung fluid and nasal brushings for analysis of macrophage activity and bacterial presence.
Follow-up
Participants are monitored for safety and effectiveness after the observational procedures, including a potential follow-up phone call.
Treatment Details
Interventions
- Non-Bronchoscopic Mini Bronchoalveolar Lavage (Other)
Find a Clinic Near You
Who Is Running the Clinical Trial?
WilliamJanssen
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Dr. Gary H. Gibbons
National Heart, Lung, and Blood Institute (NHLBI)
Chief Executive Officer since 2012
MD from Harvard Medical School
Dr. James P. Kiley
National Heart, Lung, and Blood Institute (NHLBI)
Chief Medical Officer since 2011
MD from University of California, San Francisco